Eton Pharmaceuticals, Inc. ETON R2KR3KPHARMA
Company Overview
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Why Investors Should Care
Generates a return on equity of 36.0%, reflecting efficient use of shareholder capital.
Revenue has grown at a 142.2% CAGR over the past five years.
Operating margin of 35.8% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $79.95M (+104.9% YoY); net profit $-4.60M.
- Trailing 12 Months Year-on-year growth — revenue +98.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 142.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 142.21% |
| 1 Year: | 98.60% |
Stock Price Performance
| 1 Year: | +192.06% |
| 6 Months: | +117.20% |
| 3 Months: | +18.18% |
| 1 Month: | -15.95% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)39.08 · Neutral
P/E of 125.00 is above the sector median of 25.45 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 36.0%.
- Compounding revenue at 142.2% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 125.0.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ETON Eton Pharmaceuticals, Inc. R2KR3KPHARMA | 50.00 | 125.00 | $1.43B | 0.00% | -1.57% | 35.97% | 142.21% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 500.00K | - | - | 459.00K | 99.00K | 20.00K | -161.00K | 11.90M | 3.07M | 775.00K | 2.18M | 7.36M | 3.22M | 5.30M | 12.00M | 7.03M | 7.97M | 9.07M | 10.32M | 17.28M | 18.93M | 22.46M | 21.28M | 24.27M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.42M | 7.00M | 14.60M | 8.18M | 9.53M |
| Gross Profit | - | - | - | - | - | 500.00K | - | - | - | -3.00K | -8.00K | -17.00K | 10.31M | 2.89M | 121.00K | 1.33M | 4.61M | 2.02M | 3.35M | 9.68M | 4.40M | 5.01M | 5.63M | 6.30M | 9.86M | 11.92M | 7.86M | 13.10M | 14.73M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.33M | 13.40M | 9.22M | 10.64M | 12.32M |
| Operating Income | -2.77M | -2.96M | -2.70M | -2.37M | - | -7.55M | -3.35M | -5.04M | - | -8.88M | -4.54M | -6.27M | 5.36M | -2.33M | -5.85M | -5.09M | -1.34M | -2.90M | -2.53M | 3.88M | -548.00K | -800.00K | -2.94M | 509.00K | -470.00K | -1.48M | -1.36M | 2.46M | 2.41M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 543.00K | -470.00K | -354.00K | 3.48M | 3.54M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03M | 1.04M | 592.00K | - | 840.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.50M | -2.52M | -1.96M | 1.41M | 1.57M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.00K | 66.00K | -28.00K | -69.00K | 20.00K |
| Net Income | -2.80M | -3.02M | -3.08M | -2.91M | -3.73M | -7.41M | -3.25M | -4.96M | -2.70M | -9.05M | -4.73M | -6.50M | 5.12M | -2.02M | -6.09M | -5.33M | -1.56M | -3.04M | -2.66M | 4.56M | -579.00K | -811.00K | -3.04M | 627.00K | -1.57M | -2.58M | -1.93M | 1.48M | 1.55M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.50 | -0.23 | - | 0.19 | -0.08 | -0.24 | -0.21 | -0.06 | -0.12 | -0.10 | 0.18 | -0.02 | -0.03 | -0.12 | 0.02 | -0.06 | -0.10 | -0.07 | 0.05 | 0.05 |
| R&D Expense | 1.56M | 1.27M | 1.71M | 1.54M | - | 6.46M | 1.44M | 3.42M | - | 6.27M | 1.61M | 2.83M | 886.00K | 1.99M | 2.68M | 1.62M | 690.00K | 744.00K | 535.00K | 1.12M | 615.00K | 651.00K | 2.97M | 505.00K | 1.16M | 3.71M | 1.11M | - | 1.88M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | 959.00K | 39.00K | - | 21.25M | 31.64M | 39.01M | 79.95M |
| Cost of Revenue | - | - | - | - | 6.93M | 10.58M | 15.60M | 37.21M |
| Gross Profit | - | 506.00K | -397.00K | - | 14.32M | 21.06M | 23.41M | 42.74M |
| Operating Expenses | - | - | - | - | 22.58M | 22.25M | 26.01M | 43.58M |
| Operating Income | -10.32M | -18.60M | -27.11M | - | -8.26M | -1.19M | -2.60M | -844.00K |
| EBITDA | - | - | - | - | -6.49M | -291.00K | -1.45M | 3.20M |
| Interest Expense | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | -9.02M | -689.00K | -3.81M | -4.56M |
| Tax Provision | - | - | - | - | 0 | 247.00K | 15.00K | 43.00K |
| Net Income | -12.74M | -18.32M | -27.97M | - | -9.02M | -936.00K | -3.82M | -4.60M |
| Diluted EPS | - | - | - | - | -0.36 | -0.04 | -0.15 | -0.17 |
| R&D Expense | 5.63M | 11.55M | 14.10M | 6.24M | 4.00M | 3.32M | 3.25M | 7.76M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 13.44M | 28.33M | 17.07M | 26.32M | 27.46M | 25.03M | 31.74M | 76.12M | 92.11M |
| Total Equity | -6.87M | 26.30M | 10.55M | 17.63M | 17.63M | 13.08M | 15.48M | 24.43M | 26.15M |
| Cash & Equivalents | 13.16M | 26.73M | 12.07M | 21.30M | 14.41M | 16.30M | 21.39M | 14.94M | 25.94M |
| Long Term Debt | - | - | 4.54M | 6.53M | 5.26M | 5.38M | 0 | 29.81M | 21.77M |
| Total Liabilities | 1.31M | 2.02M | 6.52M | 10.66M | 9.84M | 11.95M | 16.26M | 51.70M | 65.96M |
| Current Liabilities | 793.00K | 2.02M | 1.96M | 3.79M | 4.56M | 6.46M | 16.24M | 19.95M | 38.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.14M | -18.03M | -22.35M | -4.72M | 4.82M | 6.82M | 969.00K | 10.52M |
| Investing Cash Flow | -236.00K | -1.85M | -50.00K | -2.56M | -2.79M | -775.00K | -40.01M | -333.00K |
| Financing Cash Flow | 21.96M | 5.20M | 31.62M | 391.00K | -134.00K | -957.00K | 32.59M | 815.00K |
| Capital Expenditure | -236.00K | -1.10M | -50.00K | -9.00K | -38.00K | -0 | -26.00K | -333.00K |
| Free Cash Flow | -8.38M | -19.12M | -22.40M | -4.73M | 4.78M | 6.82M | 943.00K | 10.19M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | 52.8% | -1,017.9% | - | 67.4% | 66.6% | 60.0% | 53.5% |
| Operating Margin % | - | -1,939.6% | -69,515.4% | - | -38.9% | -3.8% | -6.7% | -1.1% |
| Net Margin % | - | -1,910.3% | -71,717.9% | - | -42.4% | -3.0% | -9.8% | -5.8% |
| ROE % | -48.4% | -173.6% | -158.7% | - | -69.0% | -6.0% | -15.7% | -17.6% |
| ROCE % | -39.2% | -123.1% | -120.4% | - | -44.5% | -7.7% | -4.6% | -1.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Opaleye Management Inc. | 10.01% | 2.86M | $157.90M |
| 2 | EcoR1 Capital, LLC | 7.60% | 2.17M | $119.91M |
| 3 | Blackrock Inc. | 6.63% | 1.90M | $104.67M |
| 4 | Nantahala Capital Management, LLC | 4.11% | 1.18M | $64.92M |
| 5 | Vanguard Capital Management LLC | 3.42% | 976.57K | $53.92M |
| 6 | Morgan Stanley | 2.69% | 767.97K | $42.40M |
| 7 | State Street Corporation | 2.46% | 701.79K | $38.75M |
| 8 | Geode Capital Management, LLC | 2.28% | 652.30K | $36.01M |
| 9 | Oberweis Asset Management Inc. | 1.75% | 501.60K | $27.69M |
| 10 | National Philanthropic Trust | 1.72% | 492.11K | $27.17M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ETON
Eton Pharmaceuticals (ETON) Stock Still Looks Rich Despite Its New Seizure Drug License - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQMGpGelVwczhPcUlmdFJ3bmJFOU5aam96U2RPU1FRaE9OQVRBUnFyOVpweWFNLS1fcmU5eXBzMGF3UXVRTXlJTkt1RTFjZHNrMmlOUk91SS1sUjF1Zy1Ic0hJc1VWT19hRExBcG1zN0xDT1c1eUtmamw1dDMxaHlKN3l5TUhzRUlNMDQ5Nm…
Eton Pharmaceuticals Has Stronger Earnings And Little Valuation Cushion (NASDAQ:ETON) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPVFpMOGkxZXpfY3JKZWlNbkY3NEc3dmgyZUJRNEdBdzNBOHY3WVpHSHNOQnhobkNab3otR05HSEdYQnJlWFBLYkoxaHVDMU85RkNFZi0tRUFwSXVDRUVPWkZpU3RYaU5xQnNOOEVqZWp1anRGaG5hb3ZvQ2xnZDZ5dHY3ajdxREVSemxzcU…
Kate Middleton shares bittersweet update on Prince George after he leaves home for Eton College - Page Six
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxOdm9rWEZXRy1MY2xJVUhxRW1aSXlMM2cxbXdkMUxzWjN3UnFXNGhRYzAxLTZNc0lUS1pnQjVNdlNIVDFyaURSLWNNbnhaMXFJRm9RS0NNS3F1a25mQ0Q1NHltdHZKRWpTa0hPZ2RBS1JVZk5DTzBCUDBKZlJZa19JNmxkWGlhR2tvTThKd0…
Eton Pharmaceuticals (ETON) Stock May Be Trading At A Premium Following Its Huge Three Year Run - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxQZU55R01Kb0tIMFJkY3lZS0s0U3ljdkYwTzVwWHR4azJqSEVzTkszZ1hLM2luWGlTdmtlSXcwR2RWVlZOM3ppN3A3SXhfenNnS3huel9zZTI4MTJmLWk5MjRSZTFIOExaSG9WYzFlWXRtSWdNUHo2TE5JUWdlQUlPaFlBbDRucm84d3lJam…
ETON Stock Surges 108% in Six Months: Here's What You Need to Know - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOWXRUWGkyVkN4M0dCZnVFbldRTDJiak82MnhHWm9aTUFma1pqT3p0MUhucGhDaG5WNnhzSTdYS2lPV3ZqZkRVb3hkTmliR1hqVFcyeXN3TFZZR1hqRW5KZTNybnUtR3p0SWNmb2xMdHhuRTRYaG1Ubm5ldU9ucDJZQ2VPM2ZGMFBOTXBIZn…
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Has Consensus Target Price of $71.50 According to Brokerages - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi-AFBVV95cUxOM2Y0M05EMUc0bnBhd1dNYXh5c091UGVZXzltU0VIVjFUYjZiZUNyWnJXSmowRXhZYjBMTHFLbjdoWENGZnQ4MWxuWUZtNHJucFFfX2l1M2FKbjhlTE1vUGd3SEItT09Uc1J3MWVlWUNlemlqVXJaMC1td2FBVk9ic05zRXlURURpbXpWTS…
ETON — Frequently Asked Questions
What is the current share price of Eton Pharmaceuticals, Inc. (ETON)?
As of 2026-10-23 16:27 PDT, Eton Pharmaceuticals, Inc. (ETON) trades at $50.00 on NasdaqGM. Its 52-week range is $14.35 to $64.43.
What is the market capitalisation of ETON?
Eton Pharmaceuticals, Inc. (ETON) has a market capitalisation of $1.43B on NasdaqGM.
What is the P/E ratio of ETON?
ETON trades at a trailing price-to-earnings (P/E) ratio of 125.00. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 33.52.
What is the return on equity (ROE) of ETON?
ETON has a return on equity (ROE) of 35.97%. Its return on capital employed (ROCE) is -1.57%.
Is ETON a good stock to buy?
This page provides a data-driven analysis of Eton Pharmaceuticals, Inc. (ETON), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.